康美德

最新新闻

• 评级变动
  Needham Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $61
  \u5e02\u573a\u8d44\u8baf · 2025/5/2
• J.P. Morgan Maintains ConMed(CNMD.US) With Hold Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Needham Downgrades ConMed(CNMD.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/6/13
• 评级变动
  Piper Sandler Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $68
  \u5e02\u573a\u8d44\u8baf · 2025/7/31
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE)
  TipRanks · 2026/3/18
• 评级变动
  Needham Maintains ConMed(CNMD.US) With Hold Rating, Announces Target Price $35.96
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• A Quick Look at Today's Ratings for ConMed(CNMD.US), With a Forecast Between $45 to $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Conmed (CNMD)
  TipRanks · 2025/12/6
• Needham Maintains ConMed(CNMD.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Piper Sandler Maintains ConMed(CNMD.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/1/29
• 评级变动
  BofA Securities Maintains ConMed(CNMD.US) With Hold Rating, Maintains Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2025/12/8
• 评级变动
  J.P. Morgan Maintains ConMed(CNMD.US) With Hold Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  Piper Sandler Maintains ConMed(CNMD.US) With Hold Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  TR | OpenAI - 4o Maintains ConMed(CNMD.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2025/8/12
• 评级变动
  J.P. Morgan Maintains ConMed(CNMD.US) With Hold Rating, Cuts Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2025/11/6
• 评级变动
  Piper Sandler Maintains ConMed(CNMD.US) With Buy Rating, Cuts Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2025/11/6
• 评级变动
  Piper Sandler Downgrades ConMed(CNMD.US) to Hold Rating, Cuts Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• BofA Securities Maintains ConMed(CNMD.US) With Hold Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/18
• 评级变动
  Wells Fargo Maintains ConMed(CNMD.US) With Hold Rating, Cuts Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/3/18

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。